Sun Pharmaceutical Industries Limited — Updates, 12-11-2025: Press Release
12-11-2025 | 09:18 am
12-11-2025 | 09:18 am
Sun Pharma's partner Philogen's Fibromun trial for Soft Tissue Sarcoma missed its primary goal (PFS). Yet, promising trends in patient survival (OS) and response rates prompt a new confirmatory Phase III study. Other studies continue.
No comments yet. Be the first to comment!
All announcements from Sun Pharmaceutical Industries Limited
